PRL-8-53

Chemical identity

PubChem carries this molecule under three compound records. A name search for PRL-8-53 returns CID 70700868, the hydrochloride, C18H22ClNO2, 319.8 g/mol, CAS 51352-87-5. A second record, CID 39988, carries the identical InChIKey and the identical formula, and it is that second record the FDA substance registry cross-references from UNII 2P77XL8HV7. The free base sits separately at CID 39989, CAS 51352-88-6, C18H21NO2, 283.4 g/mol, UNII BM2TE2XHK6. Two records for one salt is a database artefact rather than a chemical distinction, but it means a reader following a CID from one page and a CID from another can finish holding what look like two compounds.

Structurally the molecule is a benzoic acid methyl ester carrying, at the meta position, a two-carbon chain to a tertiary amine substituted with a methyl group and a benzyl group. That is a phenethylamine skeleton with an ester on the ring. It contains no amino acid residues and no peptide bond, which is worth stating plainly because article copy in the vendor-adjacent layer describes it as a memory-enhancement peptide. The 1978 paper names the tested material as 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride, so the salt is what was administered.

Coverage in the pharmacology databases is close to absent. A ChEMBL structure query on both InChIKeys returned no molecule record, so there is no ChEMBL identifier and no indexed bioactivity of any kind. openFDA returned no Drugs@FDA entry, no product label and no adverse-event report under the name. The DEA List of Controlled Substances and Regulated Chemicals, searched as a whole document, contains no occurrence of PRL-8, of either CAS number, or of the benzylmethylamino stem. PubMed does hold a MeSH supplementary concept record for the name, attached to exactly one article.

The whole human record is one paper from 1978

A PubMed search for PRL-8-53 returns a single record: Hansl and Mead, Psychopharmacology 1978;56(3):249-253, PMID 418433, from the Departments of Medicinal Chemistry and Psychiatry at Creighton University in Omaha. The record carries four publication types: Clinical Trial, Controlled Clinical Trial, Journal Article and Randomized Controlled Trial. Its publication types and CommentsCorrections field were checked on 18 August 2026: no retraction, no expression of concern, no erratum. It is also, across every database queried here, the only human study of this compound ever published.

The indexed abstract states the following and nothing else. The serial anticipation method was used under double-blind conditions. Acquisition showed slight improvement. Retention of verbal information was improved to a statistically significant degree, with most P values better than 0.01 and some better than 0.001. No significant changes were found for either visual reaction time or motor control after drug when compared with placebo values. A typographical error in the abstract, Retinetion for retention, has propagated verbatim into the citation databases and into secondary summaries.

Absent from that abstract is the entire quantitative content: no sample size, no ages, no dose, no timing, no word-list length, no retention intervals, no percentages, no adverse-event reporting. Unpaywall returns a closed open-access status for the DOI with no repository copy anywhere. The publisher's article page and its PDF endpoint both returned authentication redirects this session. Europe PMC holds the abstract only. Every specific parameter attributed to this study elsewhere was therefore checked against the one part of the paper that is public, and is not in it.

Secondary sources disagree about what the study did

Because the abstract carries no ages, no dose, no sample size, no word-list length, no interval and no effect size, every such figure quoted for this study comes from the summary layer rather than from the paper. Two web searches were run on 18 August 2026 to record what that layer holds, on the terms "PRL-8-53 1978 study 47 subjects memory 108% 152% retention" and "PRL-8-53 1978 Hansl study participants ages 24 to 86 word list 90 minutes 42.7%". The results were nootropics aggregator pages, encyclopaedia-style substance reviews, a chemical catalogue property page and vendor-adjacent article pages. No result was the primary full text, and no result cited a page or a table within it.

What recurred across those results was a participant count of 47, a single oral administration, a 12-word list, recall of 8.6 words against 7.1 on placebo, and improvement expressed as a percentage of placebo performance of 108 per cent at 24 hours and 152 per cent at one week. None of those figures appears in the indexed abstract. They recur in the same combination from page to page, which establishes that the pages share a common summary rather than that any of them read the paper.

What did not surface was as informative. The second search returned no page carrying the 42.7 per cent and 45.2 per cent pair, no page giving participant ages as 24 to 86 or 21 to 70, and no page reporting a 90-minute interval between administration and testing, although all three variants have been reported in circulation. No archived capture of any page said to carry them is held on file, so those variants are recorded here as unverifiable rather than reported as findings. A 42.7 per cent improvement and a 152 per cent improvement cannot both be the same measurement on the same population at the same timepoint, and no public document located here settles which figure, if either, was read off the paper.

The animal record is two patent specifications

Preclinical figures for this compound come from patents rather than journals. United States Patent 3,792,048, filed 29 October 1970 and granted 12 February 1974, names Nikolaus R. Hansl of Omaha, Nebraska as inventor, assignor to Pacific Research Laboratories of Santa Barbara, California; the compound appears there as Preparation 5. United States Patent 3,870,715, filed 2 April 1973 with a priority date of 9 March 1972 and granted 11 March 1975, names Hansl of Santa Barbara and carries nineteen claims built on a generic formula, naming fifteen specific compounds, of which this methyl ester is claim 3. Both specifications have long expired.

Between them the two documents state an oral LD in mice of about 500 to 700 mg/kg, tolerance studies in dog and monkey at doses as high as 50 mg/kg, chronic toxicity studies in rats with pathological examination of brains, livers and other organs at termination, reproduction studies carried through two offspring generations without evidence of malformation, spasmolysis of isolated rabbit ileum against acetylcholine, barium chloride and histamine tabulated against papaverine set at 100 per cent with this compound given as 300 per cent, and improved acquisition and retention in rats on a shock-avoidance test and a water-reward maze. Neither specification defines whether LD here means LD50 or another lethality endpoint.

Beyond the rabbit named for the ileum work, none of that carries a strain, a group size, or a route for the behavioural work, and the chronic toxicity and reproduction statements carry no duration, dose or schedule. A patent specification is written by the party seeking the patent, is not peer reviewed, and exists to support a claim of utility rather than to let a reader check a number. The single peer-reviewed animal-facing publication, Hansl's two-page note in Experientia in 1974 titled as a novel spasmolytic and CNS active agent, is indexed by PubMed with no abstract at all and is not open access, so the pharmacology most often quoted from it cannot be read.

The patent record and the standard account agree on geography. Secondary pages describe the compound as developed at Creighton University in Omaha in the 1970s, and the front page of US 3,792,048 already places Hansl in Omaha in October 1970, seven years before the 1978 paper appeared; Santa Barbara on that document is the address of the assignee company, whose initials match the compound code. The later 1973 filing gives Hansl himself a Santa Barbara address. What the documents establish is a filing history that predates the published paper by seven years, not a location that conflicts with it.

Forty-eight years without a replication

Citation counts for the 1978 paper are small enough to enumerate individually. Crossref and OpenAlex each record seven citing works; Europe PMC records two. The seven are a 1981 review of heptapeptide behavioural pharmacology, a 1983 review of psychopharmacological approaches to organic brain syndrome, a 1983 article on senile dementia in Psychiatric Annals, a 1989 book chapter on brain-enhanced drug delivery, two education-journal pieces from 1982 and 1984, and a 2023 book chapter on smart drugs in cognitive disorders. Semantic Scholar records zero citations, which reflects its coverage of pre-1990 literature rather than a contradiction.

Not one of those is a replication. No second human study of this compound appears in PubMed, in Europe PMC, or in the citing set of the first. A ClinicalTrials.gov API search on the exact term returned zero studies, and a search of the intervention field returned zero studies. A loosened token search returned two records, one a hydrocortisone study in adrenal insufficiency and one a paediatric oral semaglutide study, both false matches produced by the registry splitting the string. No trial has ever been registered.

Litigation is the usual explanation offered for the silence. Hansl did sue Creighton University, and the Nebraska Supreme Court decided Hansl v. Creighton University, 243 Neb. 21, 497 N.W.2d 63, on 19 March 1993, affirming summary judgment for the university. The reported facts are that a July 1985 settlement gave him laboratory and office access for two years, that he returned in November 1986 to find a refrigerator holding experimental compounds unplugged, and that he sued in September 1987 for breach of contract and negligence. That opinion concerns access and destroyed material. It does not name this compound, and it establishes nothing about why a 1978 result went unreplicated.

Where the compound appears now

Two recent reviews place it in the supplement and novel-substance layer rather than the clinical one. Pokrywka and colleagues, in Biology of Sport in 2025, reviewed the Polish dietary supplement market and catalogued 120 synthetic substances with claimed procognitive properties. Forty-five were classed as of unclear anti-doping status, and this compound is item 22 on that list, flagged for structural similarity to phenethylamine and its derivatives, WADA class S6. It is not itself named on the Prohibited List.

Napoletano and colleagues, in Frontiers in Psychiatry in 2020, identified it through a crawler of psychonaut web sources and filed it under miscellaneous. The supplementary entry, item 107, runs to three sentences: it describes a nootropic research chemical first synthesised in the 1970s, states that one study shows a drastic improvement in mid-term memory among users, records that information surrounding it is otherwise severely lacking, and adds that it has no recreational potential. That middle statement repeats, in a peer-reviewed review and without a figure, a sample size or a page reference, the same efficacy claim this record files as untraced, which is an instance of the propagation documented above.

Smith and colleagues, in a 2021 study of social-media descriptions of tianeptine use, record it in the paper's Table 2.0 of unique drug terms with a mention count of three. All three sources catalogue the compound in the context of what is marketed and discussed online; none reports a measurement.

No regulator anywhere has approved it as a medicine. There is no Drugs@FDA record, no product label and no adverse-event report in the openFDA datasets under the name, and no entry under the name, the CAS numbers or the chemical stem in the DEA schedules. Material sold under the code is sold as a research chemical, and no published analysis of the identity or purity of any such material was located in PubMed or Europe PMC.

What is not known

Nothing on the record establishes pharmacokinetics in any species. No absorption, distribution, metabolism, elimination or half-life measurement was located in PubMed, in Europe PMC, or in either patent specification, so the onset and duration figures in circulation rest on nothing checkable. Mechanism is equally open: there is no receptor binding assay, no transporter assay, no enzyme inhibition data and no ChEMBL bioactivity record for either InChIKey, and the neurotransmitter statements repeated everywhere trace to a two-page 1974 note that PubMed indexes without an abstract and no service consulted here could retrieve. Safety data amount to one 1978 study whose adverse-event reporting is not in the public abstract, plus unrefereed patent assertions about mouse lethality, dog and monkey tolerance and a two-generation reproduction study, none carrying a strain, a route or a group size. No peer-reviewed repeat-administration study exists. Both patent specifications assert chronic toxicity studies in rats with pathological examination of brains, livers and other organs at termination, and a two-generation reproduction study, but neither states duration, dose, strain or group size, and neither is peer reviewed. No work in aged or diseased populations, no immunogenicity or carcinogenicity assessment, and no stability or shelf-life study of any kind was located; catalogue storage figures were searched for in PubMed and Europe PMC and returned nothing. One human result has stood unreplicated for forty-eight years behind a subscription, which means the effect size most often quoted for this compound has in practice been read by very few of the people quoting it.

Questions